Aditxt Inc. (NASDAQ: ADTX) experienced a dramatic surge in trading volume and share price on Tuesday after a regulatory filing revealed a new 10% holder. The stock jumped more than 100% in heavy trading, reaching $0.0442 by early afternoon, with an intraday high of $0.0592. Over 3.2 billion shares changed hands, a massive spike for the volatile penny stock.
New Stakeholder Emerges
According to a Schedule 13D filing with the Securities and Exchange Commission, Takeover Time 2026 LLC reported beneficial ownership of 3,420,439 shares, representing 10.9% of Aditxt. The LLC, managed by Natasha Ovsepyan, acquired the shares in open-market purchases on June 12, spending approximately $50,000 from working capital. The filing indicated the stake is for investment purposes, not an attempt to control the company, though it left open the possibility of future transactions or discussions with management.
Separate Filing by Another Investor
In a related development, Jonathan Edward Hester filed a Schedule 13G, disclosing ownership of 81,592 shares, or 9.9% of Aditxt. Hester checked the box for passive investor status, indicating no intention to influence control.
Financial and Listing Challenges
Despite the stock's rally, Aditxt faces significant headwinds. The company reported just $268,852 in cash as of March 31, with a quarterly net loss of $16.2 million and minimal revenue. These factors have raised substantial doubt about its ability to continue as a going concern, and management warned that additional funding may be necessary to sustain operations.
Adding to the pressure, Nasdaq staff notified Aditxt on May 6 that its shares face delisting due to the bid price remaining below $1 for an extended period. The company is ineligible for another compliance period after previous reverse stock splits. Aditxt has requested a hearing to appeal the delisting, but there is no guarantee of success. A 1-for-27 reverse stock split took effect on May 18.
Ignite Proteomics Spin-off
Aditxt's strategic focus centers on its wholly owned subsidiary, Ignite Proteomics, which works in functional proteomics—measuring protein activity in tissue to guide cancer treatment. Earlier this month, Ignite signed a business-combination deal valuing it at approximately $150 million, with plans to spin out as a separate public company. Aditxt aims to remain listed on Nasdaq if compliance conditions are met.
Market Context
Aditxt's surge stood out in the healthcare sector on Tuesday, landing on Benzinga's list of top movers alongside Atlantic International, Boundless Bio, and HeartSciences. The SPDR S&P Biotech ETF edged up about 1.4%, while the Invesco QQQ Trust dropped roughly 2.7%.
Takeover Time's filing included a note of caution, stating that Aditxt's latest reported share count may be outdated, potentially affecting the actual ownership percentage. Investors are advised to monitor future ownership amendments, updated share counts, the Nasdaq panel's decision, and filings related to the Ignite deal for further direction.
